Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 467 | 109 | 338 |
| Samples | 422 | 96 | 319 |
| Peptides | 308 | 75 | 244 |
Function
KCNV2 · Potassium voltage-gated channel modifier subfamily V member 2
Voltage-gated potassium (Kv) channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. This gene encodes a member of the potassium voltage-gated channel subfamily V. This member is identified as a 'silent subunit', and it does not form homomultimers, but forms heteromultimers with several other subfamily members. Through obligatory heteromerization, it exerts a function-altering effect on other potassium channel subunits. This protein is strongly expressed in pancreas and has a weaker expression in several other tissues. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000382082 | Q8TDN2 | 467 | 308 |
Gene Properties
Recurrent Mutations
All 308 amino-acid changes on canonical ENST00000382082 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KCNV2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KCNV2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 19/612 3% |
| Unknown | 0/10 0% | 1/29 3% |
| Rhabdomyosarcoma | 2/33 6% | 3/171 2% |
| Colorectal Carcinoma | 17/143 12% | 63/3239 2% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 26/1390 2% |
| Gastric Carcinoma | 3/74 4% | 32/1809 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Melanoma | 3/210 1% | 26/1899 1% |
| Other Solid Cancers | 0/94 0% | 22/1515 1% |
| Cervical Carcinoma | 4/35 11% | 2/422 0% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 6/810 1% |
| Germ Cell Tumour | 2/25 8% | 0/169 0% |
| Non-Cancerous | 2/104 2% | 7/830 1% |
| Ovarian Carcinoma | 6/109 6% | 4/998 0% |
| Bladder Carcinoma | 0/58 0% | 9/956 1% |
| Wilms Tumour | 0/5 0% | 4/474 1% |
| Biliary Tract Carcinoma | 0/54 0% | 8/950 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 10/1592 1% |
| Hepatocellular Carcinoma | 1/46 2% | 12/2210 1% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Glioma | 2/52 4% | 10/2127 0% |
| Head and Neck Carcinoma | 1/85 1% | 7/1574 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Kidney Carcinoma | 1/85 1% | 7/1862 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
Mutation Distribution
Where KCNV2 is mutated · all tissues, split by cell line vs tissue
How many mutations in KCNV2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 467 mutations in KCNV2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|